Edition:
United Kingdom

Akorn Inc (AKRX.OQ)

AKRX.OQ on NASDAQ Stock Exchange Global Select Market

13.19USD
5:00pm BST
Change (% chg)

$-0.03 (-0.23%)
Prev Close
$13.22
Open
$13.19
Day's High
$13.28
Day's Low
$12.96
Volume
322,301
Avg. Vol
668,824
52-wk High
$33.61
52-wk Low
$10.76

Chart for

About

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $4,101.01
Shares Outstanding(Mil.): 124.92
Dividend: --
Yield (%): --

Financials

  AKRX.OQ Industry Sector
P/E (TTM): 33.22 30.93 32.76
EPS (TTM): 0.99 -- --
ROI: 6.80 15.07 14.61
ROE: 14.90 16.59 16.33

Fresenius CEO defends canceled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

18 May 2018

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion (3.6 billion pounds) takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

18 May 2018

UPDATE 1-Fresenius CEO defends cancelled Akorn deal

* Expects legal proceedings to conclude in 2019 (Adds details on expenses, comment on provision, analyst)

18 May 2018

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN, May 18 Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

18 May 2018

Fresenius sees Akorn lawsuit dragging on into 2019

BERLIN German healthcare group Fresenius SE said on Thursday its legal battle with Akorn over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro.

03 May 2018

Fresenius sees Akorn lawsuit dragging on into 2019

BERLIN German healthcare group Fresenius SE said on Thursday its legal battle with Akorn over its cancelled $4.7 billion (3.5 billion pounds) takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro.

03 May 2018

UPDATE 1-Fresenius sees Akorn lawsuit dragging on into 2019

* Net income 450 mln euro vs 437 mln f'cast in poll (Releads with Akorn comments)

03 May 2018

German stocks - Factors to watch on May 3

FRANKFURT, May 3 The following are some of the factors that may move German stocks on Thursday:

03 May 2018

Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

02 May 2018

UPDATE 3-Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK, May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

02 May 2018

Earnings vs. Estimates